Trials / Terminated
TerminatedNCT03072953
Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum
A Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (APD334) in Patients With Pyoderma Gangrenosum
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Arena Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Phase 2a, open label, proof-of-concept clinical study is to assess the efficacy and safety of etrasimod (APD334) in patients with Pyoderma Gangrenosum.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APD334 | APD334 active treatment |
Timeline
- Start date
- 2017-06-07
- Primary completion
- 2018-05-22
- Completion
- 2018-05-22
- First posted
- 2017-03-08
- Last updated
- 2021-06-11
- Results posted
- 2021-06-11
Locations
6 sites across 2 countries: Australia, New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03072953. Inclusion in this directory is not an endorsement.